Valuation: CombiGene AB

Market Cap 4.4Cr 44.44L 39.6L 36.66L 33.18L 62.51L 42Cr 63.25L 1.72Cr 22Cr 1.67Cr 1.63Cr 70Cr P/E 2024
-1.05x
P/E 2025 -3.62x
Enterprise Value 3.81Cr 38.53L 34.34L 31.79L 28.77L 54.2L 36Cr 54.85L 1.5Cr 19Cr 1.45Cr 1.42Cr 61Cr EV / Sales 2024
-13.3x
EV / Sales 2025 128x
Free-Float
53.9%
Yield 2024
8.4%
Yield 2025 88.5%
1 day-1.77%
1 week+1.83%
Current month-0.89%
1 month-5.53%
3 months-0.45%
6 months+20.98%
Current year-1.77%
1 week 2.15
Extreme 2.15
2.3
1 month 2.11
Extreme 2.11
2.36
Current year 1.75
Extreme 1.75
2.6
1 year 1.75
Extreme 1.75
2.87
3 years 1.27
Extreme 1.27
4.3
5 years 1.27
Extreme 1.27
14.5
10 years 1.27
Extreme 1.27
126
Manager TitleAgeSince
Chief Executive Officer 48 31/07/2025
Director TitleAgeSince
Director/Board Member 54 10/12/2024
Chairman 55 11/06/2026
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.77%+1.83%-12.25%-9.76% 45.21L
-0.21%-4.43%+44.40%+74.13% 6.63TCr
+0.82%+5.41%+8.05%+73.53% 5.48TCr
-0.22%+6.53%+11.68%+87.32% 5.29TCr
+3.28%+5.58%+26.51%+50.05% 4.41TCr
+0.51%+9.95%+22.40%+133.92% 4.37TCr
-1.15%+0.39%+263.21%+594.60% 4.21TCr
+0.10%+9.90%+16.11%+59.33% 3.4TCr
-7.13%-5.67%+28.08%-0.59% 2.62TCr
+0.69%+5.60%+36.60%+26.94% 2.34TCr
Average -0.51%+4.63%+44.48%+108.95% 3.88TCr
Weighted average by Cap. -0.08%+4.54%+50.01%+127.25%

Financials

2024 2025
Net sales 19.99L 2L 2L 2L 2L 3L 1.91Cr 3L 8L 1Cr 8L 7L 3.19Cr 3L 30.73T 27.39T 25.35T 22.95T 43.23T 29L 43.74T 1L 15.24L 1L 1L 48.58L
Net income -4.49Cr -45.37L -40.43L -37.43L -33.87L -63.82L -43Cr -64.57L -1.76Cr -23Cr -1.7Cr -1.67Cr -72Cr -1.24Cr -12.49L -11.13L -10.31L -9L -17.57L -12Cr -17.78L -48.49L -6.2Cr -46.87L -45.89L -20Cr
Net Debt -7.37Cr -74.56L -66.44L -61.51L -55.66L -1.05Cr -70Cr -1.06Cr -2.89Cr -37Cr -2.8Cr -2.74Cr -117.84Cr -58.42L -6L -5L -5L -4L -8L -5.57Cr -8L -22.92L -2.93Cr -22.16L -21.69L -9.34Cr
Projected Income Statement - Annual - CombiGene AB
Logo CombiGene AB
Larkberget AB, formerly Combigene AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Employees
1
Date Price Change Volume
21/26/21 SEK 2.220 -1.77% 12,118
20/26/20 SEK 2.260 0.00% 10,265
19/26/19 SEK 2.260 -1.31% 121
16/26/16 SEK 2.290 +3.62% 755
15/26/15 SEK 2.210 +1.38% 2,362
  1. Stock Market
  2. Stocks
  3. LARK Stock